U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C18H18N2O3
Molecular Weight 310.3471
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ORANTINIB

SMILES

CC1=C(CCC(O)=O)C(C)=C(N1)\C=C2/C(=O)NC3=C2C=CC=C3

InChI

InChIKey=NHFDRBXTEDBWCZ-ZROIWOOFSA-N
InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-

HIDE SMILES / InChI

Molecular Formula C18H18N2O3
Molecular Weight 310.3471
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Orantinib (SU-6668) is an orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. Orantinib also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells. Orantinib was in phase II clinical trials for the treatment of breast cancer. It was also in phase III clinical trials for the treatment of hepatocellular carcinoma. However, this research was terminated in 2014. The compound was originally developed by Sugen (subsidiary of Pfizer). In 1998, a co-development agreement took place between Sugen and Taiho for the compound.

Originator

Curator's Comment: # Pfizer

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3 μg/mL
200 mg/m² 1 times / day multiple, intravenous
dose: 200 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ORANTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
16.6 μg × h/mL
200 mg/m² 1 times / day multiple, intravenous
dose: 200 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ORANTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.5 h
200 mg/m² 1 times / day multiple, intravenous
dose: 200 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ORANTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
ORANTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Potent platelet-derived growth factor-beta receptor (PDGF-betaR) inhibitors: Synthesis and structure-activity relationships of 7-[3-(cyclohexylmethyl)ureido]-3-{1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl}quinoxalin-2(1H)-one derivatives.
2007 Feb
Patents

Sample Use Guides

Orantinib at 200 mg, twice per day, or placebo was given orally until TACE failure or unacceptable toxicity.
Route of Administration: Oral
Orantinib (SU-6668) inhibited PDGF-stimulated PDGFRb tyrosine phosphorylation in NIH-3T3 cells overexpressing PDGFRb at a minimum concentration of 0.03–0.1 uM. SU-6668 inhibited acidic FGF-induced phosphorylation of the FGFR1 substrate 2 (FRS-2) at concentrations of 10 uM and higher. However, SU-6668 had no detectable effect on epidermal growth factor-stimulated EGFR tyrosine phosphorylation in NIH-3T3 cells overexpressing EGFR at concentrations of up to 100 uM. Orantinib (SU-6668) inhibited VEGF-driven mitogenesis of HUVECs in a dose-dependent manner with a mean IC50 of 0.34 uM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:32:51 GMT 2025
Edited
by admin
on Mon Mar 31 18:32:51 GMT 2025
Record UNII
9RL37ZZ665
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ORANTINIB
INN   WHO-DD  
INN  
Official Name English
NSC-702827
Preferred Name English
1H-PYRROLE-3-PROPANOIC ACID, 5-((1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-
Common Name English
TSU-68
Code English
SU-006668
Code English
5-((1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3-PROPANOIC ACID
Systematic Name English
3-(2,4-DIMETHYL-5-(2-OXO-1,2-DIHYDROINDOL-3-YLIDENEMETHYL)-1H-PYRROL-3-YL)PROPIONIC ACID
Systematic Name English
Orantinib [WHO-DD]
Common Name English
3-(2,4-DIMETHYL-5-(((3Z)-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL)-1H-PYRROL-3-YL)PROPANOIC ACID
Systematic Name English
SU006668
Common Name English
3-(2,4-DIMETHYL-5-((2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL)-1H-PYRROL-3-YL)PROPIONIC ACID
Systematic Name English
orantinib [INN]
Common Name English
3-(4-(2-CARBOXYETHYL)-3,5-DIMETHYLPYRROL-2-METHYLIDENYL)-2-INDOLINONE
Common Name English
SU-6668
Code English
Classification Tree Code System Code
NCI_THESAURUS C1967
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
Code System Code Type Description
PUBCHEM
5329099
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
ChEMBL
CHEMBL274654
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
CAS
252916-29-3
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
EVMPD
SUB74858
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
NSC
702827
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
CHEBI
91088
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
EPA CompTox
DTXSID5043716
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
MESH
C412603
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
NCI_THESAURUS
C1884
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
DRUG BANK
DB12072
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
INN
9267
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
FDA UNII
9RL37ZZ665
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
SMS_ID
100000136798
Created by admin on Mon Mar 31 18:32:51 GMT 2025 , Edited by admin on Mon Mar 31 18:32:51 GMT 2025
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
METABOLITE -> PARENT
IN VITRO
METABOLITE -> PARENT
IN VITRO
METABOLITE -> PARENT
IN VITRO
METABOLITE -> PARENT
IN VITRO
Related Record Type Details
ACTIVE MOIETY